drugset / Trial / NCT00790868
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
Phase 2
Completed
180 enrolled
Boston University Charles River Campus
National Institute of Mental Health (NIMH) · collabNational Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.
Timeline
- Start
- 2008-04
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cycloserine | Small molecule | 50 mg | — |